INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

← catalyst calendar

NCT03491683 · readout in 133 d

Sponsored by Inovio Pharmaceuticals (industry) · INO — their whole pipeline →.

Phase

Phase 1/2

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

52actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2018-05-31

actual

When the study began enrolling

Primary completion

2026-12-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-12-31

estimated

The whole study's end, after follow-up

First posted

2018-04-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Glioblastoma

Interventions

Biological: INO-5401
Biological: INO-9012
Biological: Cemiplimab — also filed as REGN2810
Radiation: Radiation Therapy
Drug: Temozolomide

Primary outcome

what the primary-completion date above is the date OF

Percentage of Participants with Adverse Events (AEs)

measured From Day 0 to 30 days after the last dose of study treatment (non-serious AEs) and to 6 months after the last dose of study treatment (immune-related AEs, AEs of special interest and serious AEs) up to approximately 24 months

Permalink · INO's whole pipeline · Catalyst calendar · Every registered study · What changed